Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in Trauma Patients with Haemorrhagic Shock
NCT03903939Phase 2Completed
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hemorrhagic shock and endothelial dysfunction comparing Iloprost with Placebo (2 arms). Primary endpoint: Intensive Care Unit free days at 28 days. Started May 2019; status: completed.
02
Drugs
iloprost
03
Conditions
hemorrhagic shockendothelial dysfunction
Beyond the preview
Go deeper on NCT03903939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903939.